Elevated blood pressure (BP) is a strong, heritable[@R1]--[@R4] and modifiable driver of risk for stroke and coronary artery disease and a leading cause of global mortality and morbidity[@R5],[@R6]. At the time of analysis, genome-wide association study (GWAS) meta-analyses, and analyses of bespoke or exome content, have identified and replicated genetic variants of mostly modest or weak effect on blood pressure at over 120 loci[@R7]--[@R11]. Here, we report association analyses between BP traits and genetic variants among ˜150,000 participants in UK Biobank, a prospective cohort study of 500,000 men and women aged 40-69 years with extensive baseline phenotypic measurements, stored biological samples[@R12], and follow-up by electronic health record linkage[@R13]. We undertake independent replication in large international consortia and other cohorts, providing robust validation of our findings and new biological insights into BP regulation.

Our study design is summarized in [Fig. 1](#F1){ref-type="fig"}. Briefly, data are available for 152,249 UK Biobank participants genotyped using a customised array (including GWAS and exome content) and with genome-wide imputation based on 1000 Genomes and UK10K sequencing data[@R14]. (Further details on the UK Biobank imputation are available at the UK Biobank website.) After quality measures and exclusions (see [Online Methods](#S8){ref-type="sec"}), we study 140,886 unrelated individuals of European ancestry with two seated clinic BP measurements using the Omron HEM-7015IT device ([Supplementary Table 1](#SD3){ref-type="supplementary-material"}). We carry out GWAS analyses of systolic (SBP), diastolic (DBP) and pulse pressure (PP) using single-variant linear regression under an additive model, based on ˜9.8 million single nucleotide variants (SNVs) with minor allele frequency (MAF) ≥1% and imputation quality score (INFO) \>0.1. For SNVs with *P* \<1x10^-6^, we take forward for replication the sentinel SNV (i.e. with lowest *P*-value) at each locus, defined by linkage disequilibrium (LD) r^2^ \< 0.2, within a 1Mb interval. We similarly analyze exome content for variants with MAF ≥0.01%, including rare variants, taking into replication the sentinel SNV (*P* \< 1x10^-5^) from loci that are non-overlapping (r^2^ \<0.2) with the GWAS findings. Overall we took sentinel SNVs from 240 loci into replication: 218 from GWAS and 22 from exome analysis (r^2^ \< 0.2 and \>500kb from previously reported BP SNVs at the time of analysis and not annotated to previously reported BP genes; [Supplementary Table 2](#SD3){ref-type="supplementary-material"}).

The replication resources comprise individuals of European ancestry from a large BP meta-analysis consortium (ICBP cohorts listed in [Supplementary Note](#SD2){ref-type="supplementary-material"}) and further cohorts with 1000 Genomes data for GWAS ([Supplementary Table 3](#SD3){ref-type="supplementary-material"}), and two large BP exome consortia. We use *P* \<5x10^-8^ to denote genome-wide significance in the combined (discovery and replication) meta-analyses, with *P* \< 0.01 for support in the replication data alone and concordant direction of effect. Additionally, we take forward for replication potential secondary signals at 51 previously reported BP loci at the time of analysis (excluding the HLA region).

To better understand the functional consequences of our findings, we carry out a series of *in silico* investigations and experimental analysis of gene expression in relevant vascular tissue for selected putative functional SNVs ([Supplementary Fig. 1](#SD2){ref-type="supplementary-material"}).

Results {#S1}
=======

Genetic variants at novel and previously unvalidated loci {#S2}
---------------------------------------------------------

Of the 240 loci taken forward to replication, we validate 107 loci at *P* \< 5x10^-8^, of which 102 derive from the GWAS analysis replicated and meta-analyzed in a total of 330,956 individuals ([Tables 1](#T1){ref-type="table"}-[3](#T3){ref-type="table"}; [Supplementary Fig. 2a-c; Supplementary Fig. 3a](#SD2){ref-type="supplementary-material"}), and a further five from the exome analysis in a total of 422,604 individuals ([Tables 1](#T1){ref-type="table"}-[3](#T3){ref-type="table"} and [Supplementary Fig. 3b](#SD2){ref-type="supplementary-material"}; [Supplementary Tables 4, 5 and 6](#SD3){ref-type="supplementary-material"}). Thirty-two of these validated loci are novel findings. Since the time of analysis, the remaining 75 loci have also been reported in another study[@R15], although at least 53 of these were previously unvalidated ([Tables 1](#T1){ref-type="table"}-[3](#T3){ref-type="table"}), hence we now validate these loci for the first time. We therefore present results here for all 107 validated loci in our study. Most SNVs also show association with hypertension in the UK Biobank data, for example 93 of the 107 validated sentinel SNVs are nominally significant (*P* \< 0.01) ([Supplementary Table 7](#SD3){ref-type="supplementary-material"}).

Of the 107 validated loci, 24 are reported for association with SBP as the primary trait (most significant from combined meta-analysis), 41 for DBP and 42 for PP, although many loci are associated with more than one BP trait ([Supplementary Fig. 4](#SD2){ref-type="supplementary-material"}). For example, in the combined meta-analysis, 24 validated loci are associated with both SBP and DBP, 11 with SBP and PP, one locus with DBP and PP and four loci (*NADK-CPSF3L*, *GTF2B*, *METTL21A*-AC079767.3 and *PAX2*) with all three traits at genome-wide significance ([Fig. 2](#F2){ref-type="fig"}).

After conditional analysis on the sentinel SNV we identify an independent validated secondary SNV at five of the 107 loci ([Supplementary Table 8a; Supplementary Table 9](#SD3){ref-type="supplementary-material"}). Compared with previously reported SNVs at the time of analysis, the contribution of our validated loci increases the percentage trait variance explained by ˜1%, e.g. to 3.56% for SBP.

We report signals at known hypertension drug targets, including the angiotensin converting enzyme (*ACE*) locus (rs4308, *P* = 6.8 x 10^-14^, ACE-inhibitors), *CACNA2D2* (rs743757*, P* = 2.4 x 10^-10^, calcium channel blockers), *MME* (rs143112823 in the RP11-439C8.2 locus, *P* = 1.4 x 10^-14^, omapatrilat), *ADRA2B* (rs2579519 in the *GPAT2-FAHD2CP* locus, *P* = 4.8 x 10^-12^, beta blockers), *SLC14A2* (rs7236548, *P* = 2.0 x 10^-18^, nifedipine), and phosphodiesterase 5A (*PDE5A*; rs66887589, *P* = 3.4 x 10^-15^, sildenafil).

Additionally, we evaluate our validated SNVs, where available, in cohorts of non-European ancestry[@R9]--[@R11], while recognizing that these analyses are likely underpowered ([Supplementary Table 10](#SD3){ref-type="supplementary-material"}). We find concordance in direction of effect (*P* \<0.05) for GWAS SNVs for all three BP traits among individuals of East Asian ancestry and for DBP for South Asian ancestry, also for exome SNVs among individuals of Hispanic ancestry, pointing to cosmopolitan effects for many of the BP associated variants.

A PhenoScanner[@R16] search showed that 27 of our 107 validated sentinel SNVs (or proxies; r^2^ ≥ 0.8) exhibit genome-wide significant associations with other traits ([Supplementary Fig. 5](#SD2){ref-type="supplementary-material"}), including coronary artery disease and myocardial infarction (where BP is likely on the causal pathway[@R17]), cardiovascular risk factors (e.g. lipids, height, body mass index) and non-cardiovascular traits (e.g. lung function, cancer, Alzheimer's).

Variants at previously reported loci at time of analysis {#S3}
--------------------------------------------------------

In conditional analyses, we identify 22 secondary SNVs (17 common, one rare, four low-frequency variants) that are conditionally independent of the BP associated SNVs at 16 previously reported loci at the time of analysis ([Supplementary Table 8b](#SD3){ref-type="supplementary-material"}; [Supplementary Tables 11 and 12](#SD3){ref-type="supplementary-material"}). One rare variant (rs138582164, MAF=0.1%) in the *CDH17* locus anticipated to act as an exonic stop/gain mutation at the *GEM* gene is associated with a relatively large effect on PP (3.5 mm Hg per allele copy, [Supplementary Table 8b](#SD3){ref-type="supplementary-material"}). At three previously reported loci (*EBF1*, *PDE3A*, *JAG1*) we identify multiple independent secondary SNVs in addition to the previously reported SNVs ([Supplementary Table 11](#SD3){ref-type="supplementary-material"}).

The UK Biobank data show support (*P* \< 0.01) for 119 of 122 previously reported BP loci at the time of analysis (159 of 163 SNVs) for one or more BP traits ([Supplementary Fig. 2 a-c](#SD2){ref-type="supplementary-material"}; [Supplementary Table 13](#SD3){ref-type="supplementary-material"}). We do not show support for one SNV (rs11066280, *RPL6-ALDH1*) identified from a GWAS of East Asian ancestry[@R18], which may indicate ancestry-specific effects. We compare the MAF and effect sizes in UK Biobank with published results of previously reported variants ([Supplementary Fig. 6](#SD2){ref-type="supplementary-material"}), indicating consistency of results between the two sources of data.

We also examine findings for low-frequency and rare gene mutations previously reported to be associated with monogenic hypertension disorders[@R19] and included on the UK Biobank gene array. Despite lack of power overall, the variant with the lowest *P*-value (rs387907156; *KLH3*; MAF=0.02%) has a seemingly large effect on BP: 8.2 mm Hg (SE=4.1, *P* = 0.046) per allele for SBP; 5.6 mm Hg (SE=2.6, *P* = 0.048) for PP ([Supplementary Table 14](#SD3){ref-type="supplementary-material"}).

Functional analyses {#S4}
-------------------

We annotate the 107 validated loci to 212 genes (based on LD r^2^ ≥0.8) and seek putative function from *in silico* analyses and gene expression experiments. Candidate genes with the strongest supporting evidence are indicated in the last column of [Supplementary Table 4](#SD3){ref-type="supplementary-material"} with an indication of the supporting data source. All genome-wide significant variants in LD (r^2^\>0.8) with the variants reported here, ranked by supporting evidence, are annotated in [Supplementary Table 15](#SD3){ref-type="supplementary-material"}. Of the 107 validated sentinel SNVs three are Indels; all other variants are single nucleotide polymorphisms (SNPs). We identify non-synonymous SNVs at 13 of the 107 validated loci ([Supplementary Table 16](#SD3){ref-type="supplementary-material"}), three of which are predicted to be damaging (ANNOVAR) in *TFAP2D* (rs78648104), *NOX4* (rs56061986) and *CCDC141* (rs17362588, reported to be associated with heart rate[@R20]) ([Supplementary Fig. 5a](#SD2){ref-type="supplementary-material"}). Beyond the coding regions we identify 29 SNVs in 3'UTRs which are predicted to significantly weaken or cause loss of miRNA regulation by altering the recognition motif in seven genes, and strengthen or create target sites for miRNA binding in 13 genes (based on miRNASNP db, [Supplementary Table 16](#SD3){ref-type="supplementary-material"}).

From our expression Quantitative Trait locus (eQTL) analysis (GTEx), 59 of the 107 validated loci contain variants with eQTLs in at least one tissue ([Supplementary Table 17](#SD3){ref-type="supplementary-material"}); arterial tissue has the largest number of loci with eQTLs ([Supplementary Fig. 7](#SD2){ref-type="supplementary-material"}), with targeted *in silico* analysis showing six loci with eQTLs in arterial tissue ([Supplementary Table 16](#SD3){ref-type="supplementary-material"}). For example, the GTEx tibial artery eQTL in *SF3A3* (rs4360494) shows strong *in silico* supporting evidence, including an arterial DNase I site within which the major C allele removes a predicted AP-2 binding site ([Supplementary Fig. 8](#SD2){ref-type="supplementary-material"}). Hence we prioritized this gene for *in vitro* functional analysis (see below).

By considering all loci reported here (our 107 validated loci, and previously reported loci at the time of analysis), our DEPICT analysis identifies enrichment of expression across 31 tissues and cells ([Supplementary Fig. 9](#SD2){ref-type="supplementary-material"}; [Supplementary Table 18](#SD3){ref-type="supplementary-material"}), with greatest enrichment in the arteries (*P* = 1.9 x 10^-6^, false discovery rate (FDR) \< 1%). We use FORGE to investigate and identify significant (FDR, *P* \<0.05) cell type specific enrichment within DNase I hypersensitive sites in a range of tissues including dermal and lung microvascular endothelial cell types, and cardiac fibroblasts ([Supplementary Fig. 10](#SD2){ref-type="supplementary-material"}). For a set of curated candidate regulatory SNVs from our 107 validated loci (see [Supplementary Note](#SD2){ref-type="supplementary-material"}), widespread enrichment is found in microvascular endothelium, aortic smooth muscle, aortic fibroblasts, vascular epithelium, heart and skin ([Supplementary Fig. 10](#SD2){ref-type="supplementary-material"}). In addition, we identify significant enrichment of histone marks in a wide range of cell types, including strong enrichment seen for H3K4Me3 (an activating modification found near promoters) marks in umbilical vein endothelial cells (HUVEC) ([Supplementary Fig. 11](#SD2){ref-type="supplementary-material"}). To explore expression at the level of cardiovascular cell types specifically, we use Fantom5 reference transcript expression data (see [Online Methods](#S8){ref-type="sec"}) to cluster the 212 genes annotated to our 107 validated loci according to tissue specificity ([Supplementary Fig. 12](#SD2){ref-type="supplementary-material"}), with the significantly clustered genes forming four tissue-specific clusters, including a vascular smooth muscle cell (VSMC) and fibroblast cluster, an endothelial cell cluster (including probable endothelial cells in highly vascularized tissues), and a combined vascular cell cluster.

Additionally, Ingenuity pathway analysis and upstream transcriptional analysis show enrichment of canonical pathways implicated in cardiovascular disease, including those targeted by antihypertensive drugs, such as the alpha-adrenergic, CXCR4, endothelin signalling and angiotensin receptor pathways ([Supplementary Table 19](#SD3){ref-type="supplementary-material"}). In keeping with vascular mediation of genetic influence we identify diphenyleneiodonium, an inhibitor of flavin-containing oxidases, including NAD(P)H oxidase (NOX), which is reported to reverse endothelial dysfunction (and hypertension) in a rat model[@R21].

To identify long range target genes of non-coding variants, we use chromatin interaction (Hi-C) data from HUVEC, as enhancers and silencers often form chromatin loops with their target promoter. In most loci the strongest promoter interaction involves a gene in high LD with the SNV, but for 21 loci we find a distal potential target gene ([Supplementary Table 16](#SD3){ref-type="supplementary-material"}). Pathway analysis of the distal genes shows greatest enrichment in regulators of cardiac hypertrophy.

We evaluate pleiotropy using the Genomic Regions Enrichment of Annotations Tool (GREAT) to study enrichment of mouse phenotype and human disease ontology terms across all loci reported here. These highlight cardiovascular system abnormalities and vascular disease as the most highly enriched terms ([Supplementary Fig. 5b & 5c](#SD2){ref-type="supplementary-material"}).

Collectively evidence from eQTLs, DEPICT, DNase I sites, histone marks, Hi-C data and ontological analyses indicates predominant vascular and cardiovascular tissue involvement for genes within the BP associated loci.

We also look for association of our validated sentinel SNVs with metabolomic signatures. Three SNVs within the *NOX4*, *KCNH4* and *LHFPL2* loci show significant associations (family-wise error rate \< 5%) with lipoprotein sub-fractions from ^1^H Nuclear Magnetic Resonance (NMR) spectroscopy analysis of 2,000 Airwave study samples ([Supplementary Tables 20 and 21](#SD3){ref-type="supplementary-material"}). The results for these variants suggest a link between BP regulation and lipid metabolism. Eleven SNVs (including at *LHFPL2* locus) show association (family wise error rate \< 5%) with metabolites in blood or urine from the publicly available "Metabolomics GWAS Server" resource based on mass spectrometry[@R22],[@R23] ([Supplementary Table 21](#SD3){ref-type="supplementary-material"}), including sugar acids, sphingolipids, fatty acids, glycerophospholipids, organic acids and benzene derivatives.

Several genes and variants with putative function are highlighted in our *in silico* analysis as having biological support (e.g. eQTLs or nsSNVs) and those with novelty and tractability to laboratory investigation (e.g. expression in available tissue models) are prioritized. Sentinel variants in three genes which were highly significant in the combined meta-analysis ([Tables 2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}) are selected for experimental testing and were successfully genotyped, each for at least 100 samples. We select *ADAMTS7* due to strong biological support (e.g. mouse knockout phenotype), *SF3A3* due to eQTLs, and *NOX4* as it contains a rare nsSNV ([Supplementary Table 9](#SD3){ref-type="supplementary-material"}) in addition to common variant associations. We use quantitative polymerase chain reaction (qPCR) to study the impact of these sentinel variants on gene expression in human VSMCs and endothelial cells (ECs) (see [Online Methods](#S8){ref-type="sec"}). For *SF3A3*, the major C allele of variant rs4360494 associated with increased PP (0.278 mmHg ±0.03, *P*=3.7x10^-16^, N=307,682) is associated with *SF3A3* expression in human VSMCs, although not in endothelial cells ([Supplementary Fig. 13a](#SD2){ref-type="supplementary-material"}); and the T allele of SNV rs62012628 in *ADAMTS7* associated with lower DBP (0.238 mmHg ±0.03, *P*=5.1x10^-12^, N=244,143), is associated with reduced *ADAMTS7* expression in human VSMCs ([Supplementary Fig. 13b](#SD2){ref-type="supplementary-material"}), while the minor A allele of SNV rs2289125 at the *NOX4* locus associated with lower PP (-0.377 mmHg ±0.04, *P*=9.1x10^-22^, N=282,851) correlates with increased *NOX4* expression in ECs though not VSMCs ([Supplementary Fig. 13c](#SD2){ref-type="supplementary-material"}). Our study thus finds evidence for novel *cis*-eQTLs in *ADAMTS7* and *NOX4* in addition to validating the previously reported GTEx eQTL in *SF3A3*, and supports the vascular expression of these genes.

Genetic risk score analyses {#S5}
---------------------------

We create an unbiased genetic risk score (GRS) ([Supplementary Table 22](#SD3){ref-type="supplementary-material"}) to evaluate, in an independent cohort (Airwave, see [Online Methods](#S8){ref-type="sec"}), the impact of the combination of all loci reported here on BP levels and risk of hypertension. When compared with the lowest quintile of the distribution of the GRS, individuals \>50 years in the highest quintile have sex-adjusted mean SBP higher by 9.3 mm Hg (95% CI 6.9 to 11.7 mm Hg, *P* =1.0 x 10^-13^) and an over two-fold higher risk of hypertension (OR 2.32 95% CI 1.76 to 3.06; *P*=2.8 x 10^-9^) compared with individuals in the lowest quintile ([Fig. 3](#F3){ref-type="fig"}; [Supplementary Table 23](#SD3){ref-type="supplementary-material"}). Similar results were obtained from GRS associations with BP and hypertension within UK Biobank ([Supplementary Table 24](#SD3){ref-type="supplementary-material"}). In UK Biobank -- based on self-reported health data, record linkage to Hospital Episode Statistics and mortality follow-up data ([Supplementary Table 25](#SD3){ref-type="supplementary-material"}) -- we show that the GRS is associated with increased risk of stroke, coronary heart disease and all cardiovascular outcomes; comparing the upper and lower fifths of the GRS distribution, sex-adjusted odds ratios are 1.34 (95% CI 1.20 to 1.49, *P* =1.5×10^-7^), 1.38 (95% CI 1.30 to 1.47, *P*= 4.3×10^-23^) and 1.35 (95% CI 1.27 to 1.42, *P*=1.3×10^-25^) respectively ([Fig. 3](#F3){ref-type="fig"}; [Supplementary Table 26](#SD3){ref-type="supplementary-material"}). Results are also provided for incident-only cases ([Supplementary Table 27](#SD3){ref-type="supplementary-material"}).

Discussion {#S6}
==========

A key attribute of this study is the combination of a large, single discovery sample with standardized BP measurement and dense 1000 Genomes/UK10K imputation, yielding a high quality dataset with ˜9.8 million variants[@R14], taking advantage of major international consortia for parallel replication of common and low-frequency variants. In total we include GWAS data from 330,956 individuals and exonic SNVs from a total of 422,604 individuals. This strategy resulted in 107 robustly validated loci for BP traits, including 32 loci that have not previously been reported, and at least 53 further loci validated for the first time. Despite its size, our study is still under-powered to find low-frequency variants. Our findings are mostly common variants, with similarly modest effect sizes as variants previously reported at the time of analysis ([Supplementary Fig. 14](#SD2){ref-type="supplementary-material"}). The lack of rare variant discovery could also be due to the challenge of detecting rare variants from imputed data. There may be greater potential for identifying rare variants from the future release of genetic data for all 500,000 UK Biobank participants.

Our findings point to new biology as well as highlighting gene regions in systems that have previously been implicated in the genetics of BP. Several of our validated loci affect atherosclerosis or vascular remodelling *(ADAMTS7, THBS2, CFDP1)* and exhibit locus pleiotropy in prior genome-wide association studies for coronary artery disease or carotid intimal-media thickness[@R24]--[@R26] ([Supplementary Fig. 5a](#SD2){ref-type="supplementary-material"} and [Fig. 4](#F4){ref-type="fig"}). In previous work we have shown that expression of *ADAMTS7* is upregulated and increases vascular smooth muscle cell migration in response to vascular injury in relation to a distinct coronary artery variant (rs3825807, not in LD with our sentinel SNV; r^2^ = 0.17)[@R27]. In endothelial cells *ADAMTS7* encodes a metalloproteinase to cleave thrombospondin-1 encoded by *THBS2* which leads to reduced endothelial cell migration and plays a role in neo-intimal repair in the vessel wall[@R27]. Our functional work indicates that the allele associated with lower DBP is also associated with lower *ADAMTS7* expression in human VSMCs; this fits with the murine knockout that exhibits reduced atherosclerosis. *SF3A3* encodes a splicing factor with no prior links to BP other than our reported association and eQTL. At the *CFDP1* locus our sentinel SNV is in high LD (r^2^ = 0.95) with a variant previously associated with carotid intimal-medial thickness. Collectively our findings highlight a potential common mechanism among these genes in vascular remodelling that has previously been observed in small resistance arteries in essential hypertension[@R28].

NADPH oxidase 4 (*NOX4*) has an established role in the endothelium where it enhances vasodilatation and reduces blood pressure *in vivo*[@R29]. This oxidase generates reactive oxygen species in the endothelium and may contribute to salt sensitive hypertension in the kidney and the vasculature[@R30]--[@R32]. We found that the allele of the common variant at the *NOX4* locus correlates with increased tissue specific *NOX4* expression in endothelial cells rather than VSMCs ([Supplementary Fig. 13c](#SD2){ref-type="supplementary-material"}). *NOX4* mediates endothelial cell apoptosis and facilitates vascular collagen synthesis contributing to endothelial dysfunction and arterial stiffness, and may explain the association with PP[@R33],[@R34].

We identify several loci containing genes involved in vascular signalling and second messenger systems such as *PDE5A* and *PDE10A*[@R35]--[@R37]. The phosphodiesterase PDE5A hydrolyzes cyclic GMP and is inhibited by sildenafil which leads to vasodilatation[@R38]. This finding fits with our previous discoveries of a role for gene loci encoding elements of natriuretic peptide-nitric oxide pathway and guanylate cyclase signalling systems in BP regulation[@R18],[@R39],[@R40]. Our findings strengthen the case for evaluating the opportunity to repurpose PDE5A inhibitors for use in hypertension.

The importance of microvascular function is emphasised by the solute carrier transporters such as *SLC14A2* encoding a urea transporter, which has previously been linked to autosomal dominant Streeten type orthostatic hypotensive disorder[@R41] and BP response to nifedipine, a calcium channel blocker antihypertensive drug[@R42]. *SLC8A1* encodes a sodium calcium exchanger expressed in cardiomyocytes which alters cardiac contractility and hypertrophy and shows abnormal BP in SLC8A1 transgenic mice[@R43]. Variants at *SLC35F1* have previously been associated with resting heart rate and ventricular size which could contribute to BP elevation[@R44].

We also identify loci that are involved in cardiovascular development (*GATA2, KIAA1462, FBN2*, *FN1* and *HAND2)* such as fibrillin 2 (*FBN2*) which overlaps in action with fibrillin 1 in development of the aortic matrix[@R45]--[@R49]. In addition, fibronectin expression is increased in hypertension and in atherosclerosis but it may also play a role in the development of the heart[@R49]--[@R51].

Our analysis validates loci containing genes with prior physiological connection to BP such as *BDNF, FAM208A,* and *CACNA2D2*[@R52]--[@R54]. The neurotrophin Brain Derived Neurotrophic Factor (BDNF) modulates angiotensin 11 in the brain to elevate BP in experimental models; higher serum levels correlate with reduced risk of cardiovascular disease and mortality[@R52]. In experimental models FAM208A, which is thought to be a transcription factor, is a strong candidate for a QTL for BP[@R54]. The gene *CACNA2D2* encodes a subunit of the L-type calcium channel that is most abundantly expressed in the atrium and in neurones and may be a target for negatively chronotropic and inotropic calcium channel antagonists which reduce BP[@R55].

We examine long range genomic interactions using Hi-C, whereby the promoter region has a strong chromatin interaction with a novel SNV. One example is *EPAS1*, which is ˜200kb away from the SNV (rs11690961). It encodes hypoxia-inducible factor 2alpha, which affects catecholamine homeostasis, protects against heart failure and mutations in the gene are associated with pulmonary hypertension[@R56]. Another such gene is *INHBA*, 1.3Mb away from the SNV (rs12531683**)**, which is elevated in pulmonary hypertension and contributes to vascular remodelling by inducing expression of endothelin-1 and plasminogen activator inhibitor-1 in pulmonary smooth muscle cells[@R57].

Our observation of 9-10 mm Hg higher BP at age 50+ years when comparing the top vs bottom fifths of the BP GRS distribution has potential clinical and public health implications. We stratified by age due to a significant interaction of the GRS with age (*P* ranging between 9.96×10^-11^ and 1.16×10^-3^ for interaction with continuous BP traits, *P* = 0.012 for hypertension). Measuring the GRS in early life raises the possibility of adopting an early precision medicine approach to offset the genetic risk through lifestyle intervention (i.e. reduced sodium intake, increased potassium intake, maintenance of optimal weight, low adult alcohol consumption and regular exercise)[@R58]--[@R60]. Studies of non-pharmacologic approaches to BP control indicate that 10 mm Hg or more reduction in SBP is an achievable goal through lifestyle measures alone[@R61], while recent evidence suggests that favorable lifestyle may offset the cardiovascular sequelae associated with high genetic risk[@R62]. As the above data are observational, the extent to which adherence to lifestyle recommendations amongst high genetic risk individuals might result in favorable outcomes remains uncertain; given the substantial effect of GRS on BP by middle-age, the potential for adopting early lifestyle intervention amongst individuals at high genetic risk, along with population-wide measures to lower BP, warrants further study.

Since the completion of our study, another BP GWAS using UK Biobank data has been published[@R15], as part of a larger single-stage combined meta-analysis without replication; it reported a total of 316 loci, including 241 loci identified from the meta-analysis involving UK Biobank that were not tested for validation. Of the 107 validated loci reported in our study, 32 are discovered and validated for the first time in our analysis of UK Biobank. In addition, 75 sentinel SNVs are in LD (r^2^ ≥ 0.2) with the recently reported loci[@R15] and we validate at least 53 of these for the first time in our study (indicated by "GIU" in [Tables 1](#T1){ref-type="table"}-[3](#T3){ref-type="table"}). Furthermore we note that 49 of the reported loci from the recent study[@R15] did not validate in our large independent replication resource.

In summary we describe 107 validated loci for BP offering new biology, identifying potential new therapeutic targets and raising the possibility of a precision medicine approach to modify risk of hypertension and cardiovascular outcomes. Altogether, this represents a major advance in our understanding of the genetic architecture of BP.

Data Availability Statement {#S7}
---------------------------

The data generated during the current study are available from the UK Biobank data repository (<http://biota.osc.ox.ac.uk>), which can be accessed by researchers upon application. This includes the derived GWAS analysis results summary data from our UK Biobank discovery data for all three BP traits. The genetic and phenotypic UK Biobank data are also available upon application to the UK Biobank (<https://www.ukbiobank.ac.uk>). All replication data generated during this study are included in the published article. For example, association results of look-up variants from our replication analyses and the subsequent combined meta-analyses are contained within all [Supplementary Tables](#SD3){ref-type="supplementary-material"} provided.

Online Methods {#S8}
==============

UK Biobank data {#S9}
---------------

Our GWAS analysis is performed using data from the interim release of the first ˜150k UK Biobank (UKB) participants ([Supplementary Note](#SD2){ref-type="supplementary-material"}): ˜100k individuals from UK Biobank genotyped at ˜800,000 single nucleotide variants (SNVs) with a custom Affymetrix UK Biobank Axiom Array chip and ˜50k individuals genotyped with a custom Affymetrix UK BiLEVE Axiom Array chip from the UK BiLEVE study[@R63], a subset of UKB. SNVs were imputed centrally by UKB using a merged UK10K sequencing + 1000G imputation reference panel. UK Biobank array design and protocols are available on the UK Biobank website.

Quality control {#S10}
---------------

Following QC procedures already carried out centrally by UKB, we exclude discordant SNVs and samples with QC failures, gender discordance and high heterozygosity/missingness. We further restrict our data to a subset of individuals of European ancestry. By applying *kmeans* clustering to the Principal Component Analysis (PCA) data a total of N=145,315 Europeans remain ([Supplementary Fig. 15](#SD2){ref-type="supplementary-material"}). We use the kinship data to exclude 1^st^ and 2^nd^ degree relatives, with N=141,647 unrelated individuals remaining. Finally we restrict our data to non-pregnant individuals with two automated BP measurements available, resulting in a maximum of N=140,886 individuals for analysis ([Supplementary Note](#SD2){ref-type="supplementary-material"}).

Phenotypic data {#S11}
---------------

After calculating the mean SBP and DBP values from the two BP measurements, we adjust for medication use by adding 15 and 10 mmHg to SBP and DBP, respectively, for individuals reported to be taking BP-lowering medication (21.4% of individuals)[@R64]. PP is calculated as SBP minus DBP, according to the medication-adjusted traits. Hypertension, used in secondary analyses, is defined as: (i) SBP ≥ 140 mmHg, or (ii) DBP ≥ 90 mmHg, (iii) or taking BP-lowering medication; otherwise individuals are classified as non-hypertensive. Descriptive summary statistics are provided for all individuals ([Supplementary Table 1](#SD3){ref-type="supplementary-material"}).

Statistical methods {#S12}
-------------------

Statistical approaches used for the discovery and replication of loci are reported in detail below. We also describe methods used for: identification of secondary signals; lookups in non-European populations and for monogenic BP genes; functional and experimental methods; construction of a genetic risk score for analysis with BP traits and cardiovascular outcomes. All *P*-values are from two-sided tests.

### Analysis models {#S13}

For the GWAS, we perform linear regression analyses of the three (untransformed) continuous, medication-adjusted BP traits (SBP, DBP, PP) for all measured and imputed genetic variants in dosage format using SNPTEST software[@R65] under an additive genetic model. We carry out a similar analysis for the exome content. Quantile-quantile plots are shown in [Supplementary Fig. 16](#SD2){ref-type="supplementary-material"}. Each analysis includes the following covariates: sex, age, age[@R2], body mass index, top ten PCs and a binary indicator variable for UK Biobank vs UK BiLEVE to adjust for the different genotyping chips. We also run an association analysis within UKB for validated BP SNVs and hypertension using logistic regression under an additive model with adjustments as above. There are 76,554 hypertensive cases and the 64,384 remaining participants are treated as non-hypertensive controls. This sample size is slightly larger than the N=140,866 used in the main analyses, since participants with only one BP measurement, but with reported BP-lowering medication, could be included as hypertensive.

### Previously reported variants {#S14}

We compile a list of all SNVs previously reported to be associated with BP at the time of analysis ([Supplementary Table 13](#SD3){ref-type="supplementary-material"}). This list includes all published SNVs which have been identified and validated from previous GWAS, CardioMetabochip and exome chip projects[@R7]--[@R11]. We augment this list to include all 34,459 SNVs in Linkage Disequilibrium (LD) with these previously reported SNVs, according to a threshold of r^2^ ≥ 0.2. Results for all these variants are extracted for each of the three BP traits, to check previously reported BP associations in the UKB data, according to whether the sentinel SNV or a variant at the locus in LD (r^2^ ≥ 0.2) with it showed evidence of support (*P* \< 0.01) for association with at least one of the three BP traits.

### Replication strategy {#S15}

We use three independent external data sets for replication ([Supplementary Note](#SD2){ref-type="supplementary-material"}). First, for the GWAS analysis based on advanced 1000G imputation enhanced by UK10K data we consider SNVs with MAF ≥ 1% and perform a reciprocal replication exchange with the International Consortium of Blood Pressure (ICBP) 1000G meta-analysis (max N = 150,134). The imputation strategy for ICBP 1000G meta-analysis is based on an earlier imputation grid for the 1000G project. In addition, we recruit further cohorts with 1000G data which had not contributed to the ICBP-1000G discovery meta-analysis: ASCOT-UK (N = 3,803), ASCOT-SC (N = 2,462), BRIGHT (N = 1,791), Generation Scotland (GS) (N = 9,749), EGCUT (N = 5,468), Lifelines (N = 13,292) and PREVEND (N = 3,619). This gives a total of N = 190,318 independent replication samples for the GWAS analysis.

Second, because the UK Biobank and UK BiLEVE genotyping chips contain exome content, we sought replication from two BP exome consortia (European exome consortium and the Cohorts for Heart and Ageing research in Genome Epidemiology -- CHARGE BP exome consortium), to allow validation of coding variants and variants with lower frequency. The European exome consortium (N = 161,926) and CHARGE consortium (N = 119,792) give a total of N = 281,718 independent replication samples for the exome analysis.

Note that the lookups for GWAS and exome discovery are distinct sets of SNVs. Loci are assigned sequentially, prioritising the primary GWAS discovery first, then considering any remaining loci with non-overlapping exome content for replication in the independent exome replication resources.

### Statistical criteria for replication {#S16}

For the GWAS discovery, there are ˜9.8 million SNVs with MAF ≥ 1% and INFO \> 0.1. We consider for follow-up any SNVs with *P* \< 1x10^-6^ for any of the three BP traits. For the exome discovery, there are 149,026 exome SNVs ([Supplementary Note](#SD2){ref-type="supplementary-material"}) which were polymorphic with INFO \> 0.1; for follow-up we consider all SNVs with MAF ≥ 0.01% and *P* \< 1x10^-5^. All such SNVs are annotated to loci according to both an LD threshold of r^2^ ≥ 0.2 and a 1Mb interval region (see [Supplementary Note](#SD2){ref-type="supplementary-material"}), and signals are classified either as belonging to unvalidated loci, or being potential secondary signals at previously reported loci at the time of analysis.

### Selection of variants for follow-up {#S17}

The sentinel (most significant) SNV from each association signal is selected for follow-up, all of which are pairwise-independent by LD (r^2^ \< 0.2). For the GWAS discovery, we check that potential lookup SNVs are covered within the ICBP-1000G replication data ([Supplementary Note](#SD2){ref-type="supplementary-material"}; [Supplementary Tables 28 and 29](#SD3){ref-type="supplementary-material"}). Of the 235 novel loci containing previously unreported SNVs with MAF ≥ 1%, INFO \> 0.1 and *P*\<1x10^-6^, 218 are covered, and similarly 100 of the 123 potential secondary SNVs at 51 of the 54 previously reported BP loci are available for follow-up. For the exome discovery, by following up SNVs with MAF ≥ 0.01%, INFO \> 0.1 and *P* \< 1x10^-5^ across the three BP traits, we carry forward for replication sentinel SNVs at 22 unvalidated loci, and potential secondary SNVs at three previously reported loci at the time of analysis. We produce locus zoom plots for each of the lookup variants.

### Replication meta-analyses {#S18}

The replication and combined meta-analyses are performed within METAL software[@R66] using fixed effects inverse variance weighted meta-analysis ([Supplementary Note](#SD2){ref-type="supplementary-material"}). The combined meta-analysis of both the UKB discovery (N = 140,886) and GWAS replication meta-analysis (max N = 190,070) include a total maximum sample size of N = 330,956. For the exome combined meta-analysis, we synthesize data from the UKB discovery exome content (max N=140,866), with the replication dataset from both exome consortia (total max N=281,718), giving a maximum sample size of N=422,604.

### Validation Criteria {#S19}

In our study a signal is declared validated if it satisfies ALL of the following three criteria: (i)the sentinel SNV is genome-wide significant (*P* \< 5×10^-8^) in the combined meta-analysis for any of the three BP traits;(ii)the sentinel SNV shows evidence of support (*P* \< 0.01) in the replication meta-analysis alone for association with the most significantly associated BP trait from the combined meta-analysis (NB: *P* \< 0.01 is more stringent than a range of thresholds calculated according to False Discovery Rate (FDR), see [Supplementary Methods](#SD2){ref-type="supplementary-material"});(iii)the sentinel SNV has concordant direction of effect between the UKB discovery and the replication meta-analysis for the most significantly associated BP trait from the combined meta-analysis.

### Secondary signals {#S20}

By conditional analysis within UKB data we assess all validated secondary signals from our validated and previously reported loci at the time of analysis for independence from the sentinel or previously reported SNV, respectively ([Supplementary Note](#SD2){ref-type="supplementary-material"}). We declare a secondary signal to be independent of the previously reported SNV if there is less than a 1.5 fold difference between the main association and conditional association *P*-values on a --log10 scale, i.e. if --log10(*P*) / -log10(*P*\_cond) \< 1.5. Note that the lookup criteria already ensure that the secondary variant is not in LD (r^2^ \< 0.2) with the previously reported SNV. If more than one SNV in a region is found to be independent we undertake further rounds of iterative conditional analysis.

### Lookups in non-European ancestries {#S21}

As a secondary analysis, we look up 102 and 5 validated SNVs from the GWAS and exome analyses, respectively, in non-European ancestry samples. These comprise analysis of East Asian (N = 31,513) and South Asian (N = 33,115) ancestry data from the iGEN-BP consortium[@R11] for the GWAS lookups, and South Asian (N = 25,937), African American (N = 21,488) and Hispanic (N = 4,581) ancestry data from the CHARGE BP exome consortium[@R10] and CHD+ Exome consortium[@R9], for the exome content lookups ([Supplementary Note](#SD2){ref-type="supplementary-material"}). We carry out a binomial (sign) test based on the number of SNVs with consistent directions of effect between UKB and each of the non-European ancestry samples.

### Monogenic blood pressure gene lookups {#S22}

The UKB arrays include some rare coding variants for monogenic disorders. We collate a list of all specific mutation variants within genes known to be associated with monogenic BP disorders[@R19]. Results from the UKB association analyses for all three BP traits are extracted for any of these SNVs directly covered within the UKB dataset ([Supplementary Table 14](#SD3){ref-type="supplementary-material"}). Note that a search of proxies did not augment the list of available variants, so results are reported for the specific variants only.

### Functional analyses {#S23}

In order to prioritize associated SNVs, we use an integrative bioinformatics approach to collate functional annotation ([Supplementary Table 30](#SD3){ref-type="supplementary-material"}) at both the variant and gene level for each SNV within the BP loci (all SNVs in LD r^2^ ≥ 0.8 with the BP-associated SNVs). At the variant level we use ANNOVAR[@R67] to obtain comprehensive functional characterization of variants, including gene location, conservation and amino acid substitution impact based on a range of prediction tools including SIFT and polyphen2. All nonsynonymous variants were predicted damaging by two or more methods.

We use the University of California Santa Cruz (UCSC) genome browser to review sequence specific context of SNVs in relation to function, particularly in the Encyclopedia of DNA Elements (ENCODE) dataset[@R68]. We use the UCSC table browser to annotate SNVs in ENCODE regulatory regions. We evaluate SNVs for impact on putative micro RNA target sites in the 3' un-translated regions (3'UTR) of transcripts by a query of the miRNASNP database[@R69]. We evaluate all SNVs in LD (r^2^ ≥ 0.8) with our validated sentinel SNVs for evidence of mediation of expression quantitative trait loci (eQTL) in all 44 tissues using the Genotype-Tissue Expression (GTEx) database, in order to identify validated loci which are highly expressed, and to highlight specific tissue types which show eQTLs for a large proportion of validated loci. We further seek to identify validated loci with the strongest evidence of eQTL associations in arterial tissue, in particular.

At the gene level, we use Ingenuity Pathway Analysis (IPA) software (IPA^®^,QIAGEN Redwood City) to review genes with prior links to BP, based on annotation with the "Blood Pressure" Medline Subject Heading (MESH) term which is annotated to 684 genes. We also use IPA to identify genes which interact with BP MESH annotated genes, and evaluate genes for evidence of small molecule druggability based on queries of Chembl and Drug Gene Interaction database.

We then perform overall enrichment testing across all loci. Firstly, we use DEPICT[@R70] (Data-driven Expression Prioritized Integration for Complex Traits) to identify highly expressed tissues and cells within the BP loci. DEPICT uses a large number of microarrays (˜37k) to identify cells and tissues where the genes are highly expressed and uses precomputed GWAS phenotypes to adjust for co-founding sources. DEPICT provides a *P*-value of enrichment and false discovery rates adjusted *P*-values for each tissue/cells tested.

Furthermore, to investigate regulatory regions, we employ a two tiered approach to investigate cell type specific enrichment within DNase I sites using FORGE, which tests for enrichment of SNVs within DNase I sites in 123 cell types from the Epigenomics Roadmap Project and ENCODE[@R71] ([Supplementary Note](#SD2){ref-type="supplementary-material"}). Validated sentinel SNVs from our study are analysed along with previously reported SNVs at the time of analysis and secondary signals (with *P*-value \< 1×10^-4^) to evaluate the overall tissue specific enrichment of BP associated variants. In a second analysis we use FORGE (with no LD filter) to investigate directly our curated candidate regulatory SNVs for overlap with cell-specific DNase I signals.

GenomeRunner[@R72] is used to search for enrichment of validated and previously reported sentinel SNVs with histone modification mark genomic features ([Supplementary Note](#SD2){ref-type="supplementary-material"}). Relevant cardiovascular tissue expression is investigated using Fantom5 reference transcript expression data ([fantom.gsc.riken.jp/5](fantom.gsc.riken.jp/5)) ([Supplementary Note](#SD2){ref-type="supplementary-material"}).

We use IPA (IPA^®^,QIAGEN Redwood City) to identify biological pathways and transcriptional upstream regulators enriched for genes within the BP loci. The transcriptional upstream regulator analysis aims to identify transcription factors, compounds, drugs, kinases and other molecules, for which the target is one of the BP genes under investigation.

We query SNVs against PhenoScanner[@R16] to investigate trait pleiotropy, extracting all association results with nominal significance at *P* \< 0.05 for full reporting ([Supplementary Table 16](#SD3){ref-type="supplementary-material"}), and then extract genome-wide significant results to highlight the validated loci with strongest evidence of association with other traits ([Supplementary Fig. 5a](#SD2){ref-type="supplementary-material"}). We also use the Genomic Regions Enrichment of Annotations Tool (GREAT) to study gene set enrichment of mouse phenotype and disease ontology terms within our validated and previously reported loci at the time of analysis, using default SNV to gene mapping settings[@R73].

We carry out metabolomics analysis using two sets of data. First we use ^1^H NMR lipidomics data on plasma from a subset of 2,000 participants of the Airwave Health Monitoring Study[@R74],[@R75] ([Supplementary Note](#SD2){ref-type="supplementary-material"}). For each validated BP-associated SNV we ran association tests with the lipidomics data using linear regression analyses, adjusted for age and sex. We computed significance thresholds using a permutation derived family wise error rate (5%) to account for the high correlation structure of these data (ENT=35)[@R76]. We also test each validated SNV against published genome-wide vs metabolome-wide associations in plasma and urine using publicly available data from the "Metabolomics GWAS Server" to identify metabolites that have been associated with variants of interest at *P* \< 3.0 x 10^-4^ (Bonferroni corrected *P* for validated signals)[@R22],[@R23].

### Experimental methods {#S24}

We prioritize genes for laboratory testing on the basis of evidence for SNV function (including coding variants, eQTLs and Hi-C interactions), biological support for relevance to BP (from literature review) and transgenic phenotype. We perform genotyping and Quantitative Reverse-Transcription Polymerase Chain Reaction (q RT-PCR) for the selected sentinel variants of interest using human vascular smooth muscle cells and endothelial cells and test for expression levels ([Supplementary Note](#SD2){ref-type="supplementary-material"}; [Supplementary Table 31](#SD3){ref-type="supplementary-material"}). All three SNVs were tested using an additive model.

### Genetic risk scores {#S25}

Genetic risk scores (GRS) are constructed using the independent Airwave study[@R74] data to assess the combined effect of the BP-associated variants on BP and risk of hypertension ([Supplementary Note](#SD2){ref-type="supplementary-material"}), whilst avoiding bias by "winners curse". We create weighted GRSs for all pairwise-independent, LD-filtered (r^2^ \< 0.2) previously reported variants at the time of analysis and our validated variants (sentinel and secondary SNVs) combined, using available SNVs ([Supplementary Table 22](#SD3){ref-type="supplementary-material"}). For the previously reported variants, we weight BP increasing alleles by the beta coefficients from the UKB analysis. For our validated variants, beta coefficients of the replication meta-analysis are used as independent, unbiased weights.

For the variance explained analyses within the independent Airwave cohort, we use three trait-specific GRSs (SBP, DBP, PP). Each GRS includes all variants, but weights are trait-specific, using the beta coefficients from the analysis of each of the three different BP traits, e.g. the SBP-GRS is weighted by the beta coefficients from the SBP-GWAS. To calculate the percent of variance for each BP trait explained by its corresponding trait-specific GRS, not accounted for by known factors, we generate the residuals from the regression model of each trait against covariates of age, age^2^, sex and body mass index. We then fit a second linear model for the trait residuals with all the variants in the GRS plus the top 10 PCs.

For risk score analyses we calculate a single BP GRS, as the average of the SBP and DBP GRSs. We standardize the average GRS to have mean of zero and standard deviation of one. We assess the association of the continuous average GRS variable with each BP trait by simple linear regression. We also run a logistic regression to examine the association of the average GRS with risk of hypertension. We perform each analysis both with and without adjustment for sex. We test for interaction between age (\< 50, and ≥50 years) and the effect of the GRS on BP. We then compare BP levels and risk of hypertension for individuals in the top and bottom 20% of the GRS distribution at ≥50 years using linear and logistic regression, respectively.

We also assess the association of the average BP GRS with cardiovascular outcomes in the UKB data. We include all pairwise-independent previously reported BP variants at the time of analysis, and our validated variants. We use logistic regression with binary outcome variables for coronary heart disease, stroke and cardiovascular disease (see [Supplementary Note](#SD2){ref-type="supplementary-material"}) and GRS as explanatory variable (with and without sex adjustment).
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![Study design schematic for discovery and validation of loci. N: sample size; QC: Quality Control; PCA: Principal Component Analysis; BP: blood pressure; SBP: systolic BP; DBP: diastolic BP; PP: pulse pressure; SNVs: single nucleotide variants; BMI: body mass index; UKB: UK Biobank; UKBL: UK BiLEVE; GWAS: Genome-wide association study; MAF: Minor Allele Frequency; *P*: P-value; LD: Linkage Disequilibrium; 1000G: 1000 Genomes. UKBBvsUKBL: a binary indicator variable for UK Biobank vs UK BiLEVE to adjust for the different genotyping chips](emss-70782-f001){#F1}

![Venn diagram of 107 validated loci from our study. This shows concordance of significant associations across the three blood pressure phenotypes for the 107 validated sentinel variants ([Tables 1](#T1){ref-type="table"}-[3](#T3){ref-type="table"}) from both the GWAS and exome analyses, according to genome-wide significance in the combined meta-analysis. The locus names labelled within the Venn Diagram correspond to [Tables 1](#T1){ref-type="table"}-[3](#T3){ref-type="table"}, and relate to the nearest annotated gene. The loci names in bold font highlight the 32 novel loci which are reported for the first time in our study.](emss-70782-f002){#F2}

![Distribution of Genetic Risk Score (GRS) and its relationship with blood pressure, hypertension and CVD outcomes. The GRS is based on all reported loci: both previously reported loci at the time of analysis; and all validated blood pressure variants from this study. (a) Distribution of GRS in Airwave and sex-adjusted odds ratio of hypertension in age 50+ comparing each of the upper four GRS quintiles with the lowest quintile; dotted lines represent the upper 95% confidence intervals. (b) Mean blood pressures and standard deviation in bracket in Airwave age 50+ across GRS quintiles. (c) Distribution of GRS in UKB and sex-adjusted odds ratio of CVD, CAD and stroke comparing each of the upper four GRS quintiles with the lowest quintile; dotted lines represent the upper 95% confidence intervals. (d) Count of CVD, CAD and stroke (events and deaths) across GRS quintiles in UKB participants](emss-70782-f003){#F3}

![Summary of gene cardiovascular expression from validated loci. Genes are shown on the basis of their tissue expression and supporting evidence summarised in [Supplementary Table 16](#SD3){ref-type="supplementary-material"}, based on Knockout (KO) phenotype, previously reported blood pressure biology or a strong functional rationale: eQTL (expression Quantitative Trait Loci), nsSNV (non-synonymous SNV), Hi-C. Multiple lines of evidence indicate the central importance of the vasculature in blood pressure regulation and we thus highlight existing drugged (\*) and druggable (\#) targets among these genes. Illustrations used elements with permission from Servier Medical Art*.* We note that some druggable genes may carry a safety liability, such as *GJA1*, which has known association with QT interval[@R20]](emss-70782-f004){#F4}

###### Loci validated with SBP as primary trait: combined meta-analysis results from (a) GWAS and (b) Exome for the sentinel variant

  \(a\) GWAS                                                                                                    
  ------------------------- ---- ------------- ------------- --- ------ --------- -------- ------ ------------- -----
  **NADK-CPSF3L**           1    1,685,921     rs139385870   D   0.5    281,890   -0.352   0.05   1.3x10^-12^   GIU
  **CELA2A**                1    15,798,197    rs3820068     A   0.81   310,776   0.425    0.06   1.1x10^-12^   GIU
  **GTF2B**                 1    89,360,158    rs10922502    A   0.62   323,666   -0.382   0.05   2.2x10^-15^   GIU
  **FOSL2**                 2    28,635,740    rs7562        T   0.52   319,942   0.263    0.05   1.9x10^-8^    
  **PRKD3**                 2    37,517,566    rs13420463    A   0.77   330,307   0.356    0.05   7.0x10^-11^   GIU
  **METTL21A-AC079767.3**   2    208,526,140   rs55780018    T   0.54   304,567   -0.391   0.05   5.9x10^-16^   GIU
  **RYK**                   3    134,000,025   rs9859176     T   0.4    322,428   0.322    0.05   1.3x10^-11^   G
  **NPNT**                  4    106,911,742   rs13112725    C   0.76   306,370   0.435    0.06   1.5x10^-14^   GIU
  **TMEM161B**              5    87,514,515    rs10059921    T   0.08   298,543   -0.526   0.09   4.0x10^-9^    GIU
  **FBN2**                  5    127,868,199   rs6595838     A   0.3    328,401   0.344    0.05   7.6x10^-12^   GIU
  **CASC15**                6    22,130,601    rs6911827     T   0.45   326,471   0.296    0.05   2.0x10^-10^   GIU
  **TFAP2D**                6    50,683,009    rs78648104    T   0.92   305,426   -0.481   0.08   1.3x10^-8^    
  **MKLN1**                 7    131,059,056   rs13238550    A   0.4    325,647   0.331    0.05   1.9x10^-12^   
  **HIPK2**                 7    139,463,264   rs1011018     A   0.2    325,110   -0.329   0.06   1.5x10^-8^    
  **ZFAT**                  8    135,612,745   rs894344      A   0.6    329,834   -0.258   0.05   3.2x10^-8^    
  **PAX2**                  10   102,604,514   rs112184198   A   0.1    323,791   -0.659   0.08   3.6x10^-18^   GIU
  **MCF2L**                 13   113,636,156   rs9549328     T   0.23   313,787   0.318    0.06   1.5x10^-8^    GI
  **FERMT2**                14   53,377,540    rs9888615     T   0.29   326,235   -0.318   0.05   3.5x10^-10^   GIU
  **PPP2R5E**               14   63,928,546    rs8016306     A   0.8    329,869   0.335    0.06   3.7x10^-9^    
  **ABHD17C**               15   81,013,037    rs35199222    A   0.45   323,407   0.322    0.05   5.2x10^-12^   GI
  **CFDP1**                 16   75,331,044    rs11643209    T   0.42   309,242   -0.339   0.05   1.8x10^-12^   GI
  **CRK**                   17   1,333,598     rs12941318    T   0.49   299,739   -0.269   0.05   2.5x10^-8^    GIU
  **ACOX1**                 17   73,949,045    rs2467099     T   0.22   326,401   -0.307   0.06   3.3x10^-8^    GIU
                                                                                                                
  **(b) Exome**                                                                                                 
  **SSPN**                  12   26,438,189    rs6487543     A   0.77   244,842   0.3      0.05   6.3x10^-10^   

Locus: named according to nearest annotated gene(s); Chr: chromosome; Pos: build 37; EA: effect allele; EAF: EA frequency in UK Biobank; Beta: effect estimate; SE: Standard Error of effect; P: P-value; N: total sample size analyzed; Note: indicates loci published since our analysis[@R15] from GERA (G), GERA+ICBP(HapMap) (GI) or GERA+ICBP(HapMap)+UKB (GIU) analyses.

###### Loci validated with DBP as primary trait: combined meta-analysis results from (a) GWAS and (b) Exome for the sentinel variant

  \(a\) GWAS                                                                                              
  ------------------- ---- ------------- ------------- --- ------ --------- -------- ------ ------------- -----
  **chr1mb25**        1    25,030,470    rs6686889     T   0.25   322,575   0.185    0.03   3.6x10^-9^    
  **DNM3**            1    172,357,441   rs12405515    T   0.56   328,543   -0.165   0.03   1.4x10^-9^    GIU
  **GPATCH2**         1    217,718,789   rs12408022    T   0.26   320,983   0.198    0.03   2.4x10^-10^   GIU
  **CDC42BPA**        1    227,252,626   rs10916082    A   0.73   327,636   -0.177   0.03   8.4x10^-9^    
  **WNT3A**           1    228,191,075   rs2760061     A   0.47   312,761   0.23     0.03   2.1x10^-16^   GIU
  **SDCCAG8**         1    243,471,192   rs953492      A   0.46   325,253   0.22     0.03   7.4x10^-16^   G
  **ADCY3**           2    25,139,596    rs55701159    T   0.89   321,052   0.285    0.04   7.2x10^-11^   
  **SLC8A1**          2    40,567,743    rs4952611     T   0.58   309,395   -0.157   0.03   4.0x10^-8^    
  **AC016735.1**      2    43,167,878    rs76326501    A   0.91   318,127   0.419    0.05   3.6x10^-18^   
  **GPAT2-FAHD2CP**   2    96,675,166    rs2579519     T   0.63   311,557   -0.197   0.03   4.8x10^-12^   
  **TEX41**           2    145,646,072   rs1438896     T   0.3    329,278   0.234    0.03   2.0x10^-15^   GIU
  **CCDC141**         2    179,786,068   rs79146658    T   0.91   321,318   -0.311   0.05   2.4x10^-10^   G
  **TMEM194B**        2    191,439,591   rs7592578     T   0.19   304,672   -0.24    0.04   9.5x10^-12^   
  **TNS1**            2    218,668,732   rs1063281     T   0.6    315,354   -0.2     0.03   1.3x10^-12^   GIU
  **CAMKV-ACTBP13**   3    49,913,705    rs36022378    T   0.8    319,983   -0.202   0.03   4.7x10^-9^    GIU
  **CACNA2D2**        3    50,476,378    rs743757      C   0.14   328,836   0.245    0.04   2.4x10^-10^   GIU
  **FAM208A**         3    56,726,646    rs9827472     T   0.37   323,058   -0.177   0.03   4.3x10^-10^   GIU
  **RP11-439C8.2**    3    154,707,967   rs143112823   A   0.09   297,343   -0.403   0.05   1.4x10^-14^   GIU
  **SENP2**           3    185,317,674   rs12374077    C   0.35   327,513   0.163    0.03   9.2x10^-9^    GIU
  **PDE5A**           4    120,509,279   rs66887589    T   0.52   324,397   -0.215   0.03   3.4x10^-15^   GIU
  **POC5**            5    75,038,431    rs10078021    T   0.63   314,172   -0.164   0.03   1.3x10^-8^    G
  **CPEB4**           5    173,377,636   rs72812846    A   0.28   312,601   -0.209   0.03   2.2x10^-11^   GIU
  **PKHD1**           6    51,832,494    rs13205180    T   0.49   325,419   0.168    0.03   7.0x10^-10^   GIU
  **PDE10A**          6    166,178,451   rs147212971   T   0.06   296,010   -0.36    0.06   1.6x10^-9^    GIU
  **SLC35F1**         6    118,572,486   rs9372498     A   0.08   330,625   0.334    0.05   1.8x10^-11^   GIU
  **SNX31**           8    101,676,675   rs2978098     A   0.54   324,424   0.165    0.03   1.5x10^-9^    
  **RP11-273G15.2**   8    144,060,955   rs62524579    A   0.53   268,645   -0.175   0.03   3.8x10^-9^    GIU
  **MTAP**            9    21,801,530    rs4364717     A   0.55   327,173   -0.175   0.03   1.3x10^-10^   
  **BDNF**            11   27,728,102    rs11030119    A   0.31   330,002   -0.163   0.03   2.9x10^-8^    GIU
  **MYEOV**           11   69,079,707    rs67330701    T   0.09   276,760   -0.367   0.05   2.1x10^-12^   GIU
  **RP11-321F6.1**    15   66,869,072    rs7178615     A   0.37   318,076   -0.179   0.03   2.6x10^-10^   
  **ADAMTS7**         15   79,070,000    rs62012628    T   0.29   244,143   -0.238   0.03   5.1x10^-12^   
  **chr15mb95**       15   95,312,071    rs12906962    T   0.68   319,952   -0.221   0.03   5.6x10^-14^   GIU
  **PPL**             16   4,943,019     rs12921187    T   0.43   326,469   -0.174   0.03   2.5x10^-10^   G
  **FBXL19**          16   30,936,743    rs72799341    A   0.24   324,502   0.185    0.03   5.8x10^-9^    GIU
  **CMIP**            16   81,574,197    rs8059962     T   0.42   319,839   -0.17    0.03   1.3x10^-9^    
  **ACE**             17   61,559,625    rs4308        A   0.37   319,394   0.213    0.03   6.8x10^-14^   GIU
  **MAPK4**           18   48,142,854    rs745821      T   0.76   330,954   0.189    0.03   1.4x10^-9^    
  **CCNE1**           19   30,294,991    rs62104477    T   0.33   320,347   0.177    0.03   1.2x10^-9^    GIU
  **PLCB1**           20   8,626,271     rs6108168     A   0.25   327,368   -0.211   0.03   1.1x10^-11^   
                                                                                                          
  **(b) Exome**                                                                                           
  **MRAS**            3    138,119,952   rs2306374     T   0.84   281,715   -0.184   0.03   7.4x10^-9^    GIU

Locus: named according to nearest annotated gene(s); Chr: chromosome; Pos: build 37; EA: effect allele; EAF: EA frequency in UK Biobank; Beta: effect estimate; SE: Standard Error of effect; P: P-value; N: total sample size analyzed; Note: indicates loci published since our analysis[@R15] from GERA (G), GERA+ICBP(HapMap) (GI) or GERA+ICBP(HapMap)+UKB (GIU) analyses.

###### Loci validated with PP as primary trait: combined meta-analysis results from (a) GWAS and (b) Exome for the sentinel variant

  \(a\) GWAS                                                                                                    
  ------------------------- ---- ------------- ------------- --- ------ --------- -------- ------ ------------- -----
  **chr1mb9**               1    9,441,949     rs9662255     A   0.43   310,618   -0.207   0.03   1.9x10^-10^   GIU
  **SF3A3**                 1    38,455,891    rs4360494     C   0.55   282,851   0.278    0.03   3.7x10^-16^   G
  **RP4-710M16.1-PPAP2B**   1    56,576,924    rs112557609   A   0.35   325,952   0.227    0.03   6.8x10^-12^   
  **FGGY**                  1    59,653,742    rs3889199     A   0.71   329,486   0.351    0.03   1.8x10^-24^   G
  **C2orf43**               2    20,881,840    rs2289081     C   0.36   329,140   -0.223   0.03   5.5x10^-12^   GI
  **PRKCE**                 2    46,363,336    rs11690961    A   0.88   327,847   0.34     0.05   3.9x10^-12^   GIU
  **CEP68**                 2    65,283,972    rs74181299    T   0.62   324,224   0.23     0.03   9.6x10^-13^   GIU
  **TCF7L1**                2    85,491,365    rs11689667    T   0.54   330,634   0.176    0.03   1.7x10^-8^    GIU
  **FN1**                   2    216,300,482   rs1250259     A   0.74   325,485   -0.314   0.04   8.7x10^-19^   G
  **GATA2**                 3    128,201,889   rs62270945    T   0.03   279,925   0.607    0.1    1.8x10^-9^    GIU
  **PALLD**                 4    169,717,148   rs1566497     A   0.42   320,948   0.236    0.03   1.9x10^-13^   GI
  **chr4mb174**             4    174,584,663   rs17059668    C   0.92   313,277   -0.332   0.06   2.8x10^-8^    
  **LHFPL2**                5    77,837,789    rs10057188    A   0.46   325,985   -0.205   0.03   6.7x10^-11^   GIU
  **GJA1**                  6    121,781,390   rs11154027    T   0.47   316,708   0.207    0.03   1.1x10^-10^   
  **ESR1**                  6    152,397,912   rs36083386    I   0.11   323,303   0.439    0.05   1.5x10^-18^   G
  **FNDC1**                 6    159,699,125   rs449789      C   0.14   325,584   0.359    0.05   2.4x10^-15^   GIU
  **THBS2**                 6    169,587,103   rs1322639     A   0.78   319,866   0.316    0.04   4.8x10^-17^   G
  **SUGCT**                 7    40,447,971    rs76206723    A   0.1    328,162   -0.346   0.05   7.4x10^-12^   GIU
  **SLC20A2**               8    42,324,765    rs2978456     T   0.55   304,964   -0.188   0.03   1.2x10^-8^    GIU
  **TRAPPC9**               8    141,060,027   rs4454254     A   0.63   330,022   -0.261   0.03   5.1x10^-16^   
  **SCAI**                  9    127,900,996   rs72765298    T   0.87   316,271   -0.374   0.05   2.7x10^-14^   GI
  **KIAA1462**              10   30,317,073    rs9337951     A   0.34   299,646   0.28     0.04   2.5x10^-15^   G
  **ARHGAP12**              10   32,082,658    rs10826995    T   0.71   327,373   -0.212   0.03   1.1x10^-9^    GIU
  **PRDM11**                11   45,208,141    rs11442819    I   0.11   326,483   -0.279   0.05   7.1x10^-9^    GIU
  **NOX4**                  11   89,224,453    rs2289125     A   0.21   307,682   -0.377   0.04   9.1x10^-22^   G
  **CEP164**                11   117,283,676   rs8258        T   0.38   327,038   0.236    0.03   2.9x10^-13^   G
  **CCDC41**                12   94,880,742    rs139236208   A   0.1    291,244   -0.363   0.06   1.6x10^-10^   G
  **RP11-61O1.1**           14   98,587,630    rs9323988     T   0.63   327,551   -0.212   0.03   4.1x10^-11^   GIU
  **VAC14**                 16   70,755,610    rs117006983   A   0.01   250,766   0.986    0.14   4.1x10^-12^   
  **CDH13**                 16   83,045,790    rs7500448     A   0.75   321,958   0.329    0.04   1.1x10^-19^   G
  **KIAA0753**              17   6,473,828     rs7226020     T   0.56   303,389   -0.256   0.03   2.3x10^-14^   GIU
  **TP53-SLC2A4**           17   7,571,752     rs78378222    T   0.99   294,053   0.904    0.14   1.8x10^-10^   GIU
  **KCNH4-HSD17B1**         17   40,317,241    rs79089478    T   0.97   318,326   0.584    0.1    3.1x10^-9^    
  **PYY**                   17   42,060,631    rs62080325    A   0.66   315,689   -0.186   0.03   4.0x10^-8^    
  **MRC2**                  17   60,767,151    rs740698      T   0.56   311,450   -0.228   0.03   3.1x10^-12^   
  **SLC14A2**               18   43,097,750    rs7236548     A   0.18   330,075   0.352    0.04   2.0x10^-18^   G
  **SLC24A3**               20   19,465,907    rs6081613     A   0.28   315,546   0.263    0.04   1.6x10^-13^   GIU
  **ARVCF**                 22   19,967,980    rs12628032    T   0.3    310,292   0.24     0.03   5.5x10^-12^   GIU
  **XRCC6**                 22   42,038,786    rs73161324    T   0.05   267,722   0.496    0.07   2.8x10^-11^   
                                                                                                                
  **(b) Exome**                                                                                                 
  **CD34**                  1    208,024,820   rs12731740    T   0.1    279,078   -0.249   0.04   1.1x10^-8^    
  **ZNF638**                2    71,627,539    rs3771371     T   0.57   280,285   -0.16    0.03   5.8x10^-9^    GIU
  **CRACR2B**               11   828,916       rs7126805     A   0.73   145,162   0.222    0.04   3.3x10^-9^    

Locus: named according to nearest annotated gene(s); Chr: chromosome; Pos: build 37; EA: effect allele; EAF: EA frequency in UK Biobank; Beta: effect estimate; SE: Standard Error of effect; P: P-value; N: total sample size analyzed; Note: indicates loci published since our analysis[@R15] from GERA (G), GERA+ICBP(HapMap) (GI) or GERA+ICBP(HapMap)+UKB (GIU) analyses.

[^1]: A full list of ICBP consortium members and affiliations can be found at the end of the paper.
